Skip to main content
. 2013 Jun 21;7:519–527. doi: 10.2147/DDDT.S31442

Figure 2.

Figure 2

Schema for Phase III tivozanib trial.

Abbreviations: ccRCC, clear cell renal cell carcinoma; ECOG, Eastern Cooperative Oncology Group (performance score); mTOR, mammalian target of rapamycin; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; R, randomization; TIVO-1, Tivozanib Versus Sorafenib in 1st line Renal Cell Carcinoma; VEGF, vascular endothelial growth factor.